On October 16, 2026, NANO-X
IMAGING LTD. (the “Company”) issued a press release providing a brief business update and furnishing certain preliminary
unaudited financial data for the Company’s third quarter ended September 30, 2026. A copy of that press release is attached to
this Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) as Exhibit 99.1.
The contents of this Form
6-K, including Exhibit 99.1 hereto, are hereby incorporated by reference into the Company’s shelf registration statement on Form
F-3 (File No. 333-294302), initially filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”)
on March 13, 2026 and declared effective by the SEC on March 30, 2026 (the “Form F-3”), including the prospectus supplements,
dated July 23, 2026 and August 5, 2026, filed by the Company with the SEC pursuant to Rule 424(b)(5) under the Securities Act of 1933,
as amended, on July 24, 2026 and August 7, 2026, respectively, which supplement the prospectus forming a part of the Form F-3.
Exhibit
99.1
Nanox
Provides Business Update and Furnishes Certain Preliminary Unaudited Financial Data for third Quarter Ended September 30, 2026
PETACH
TIKVA, Israel — October 16, 2026 — NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”),
an innovative medical imaging technology company, today provided a brief business update and furnished certain preliminary unaudited
financial data for the third quarter ended September 30, 2026. The preliminary figures are estimates based on currently available information,
are preliminary and unaudited, and are subject to change upon completion of the Company’s financial close process, final adjustments,
management review and other internal procedures, review by its independent auditors. The Company’s final reported unaudited financial
results for the third quarter of 2026 may differ materially from the preliminary figures and will be reported in a subsequent press release
at a later date.
Business
Update
Nanox.AI: Nanox AI enters into a distribution
agreement with Technologic s.r.l., an Affiliate of Tecnologie Avanzate, to commercialize Nanox.AI’s Bone Solution in Italy. Collaboration
leverages Tecnologie Avanzate’s experience, established healthcare industry relationships, and expertise in the Italian market.
TIME Best Inventions Recognition: Nanox selected
as one of TIME’s Best Inventions of 2026 for its Nanox.ARC X. Nanox.ARC X recognized among the “world’s most groundbreaking
innovations” and for its approach to making advanced medical imaging more accessible.
Preliminary
Financial Data for the Three Months Ended September 30, 2026
Cautionary
Note Regarding Preliminary Financial Data
The
preliminary financial data set forth below represents the Company’s current estimates based on information available as of the
date of this press release. These estimates are preliminary and unaudited, have been prepared by and are the responsibility of the Company’s
management, and are subject to the completion of the Company’s financial closing procedures, final adjustments, management review
and other internal review procedures, and other developments that may arise between now and the time the financial results are finalized.
In
addition, the Company’s independent registered public accounting firm has not audited, reviewed, compiled, or applied agreed-upon
procedures with respect to the preliminary financial results. Accordingly, it does not express an opinion or any other form of assurance
with respect thereto.
Preliminary
Revenue Data
On
a preliminary unaudited basis, the Company expects its revenue to be approximately $4.3 to $4.4 million for the three months ended September
30, 2026 (the “Reported Period”), compared to $3.4 million for the corresponding three-month period in 2025 (the “Comparable
Period”). During the Reported Period, the Company generated revenue through teleradiology services, the sale and deployment
of its imaging systems and its AI and software solutions.
The Company’s revenue from teleradiology
services for the Reported Period was approximately $3.1 million, compared to revenue of $3.1 million in the Comparable Period.
During the Reported Period,
the Company generated revenue through the sale and deployment of its imaging systems and OEM services which amounted to approximately
$0.3 million for the Reported Period, compared to revenue of $0.2 million in the Comparable Period. This increase in revenue is related
mainly to an additional Nanox.ARC CapEx agreement.
The Company’s
revenue from its AI and software solutions for the Reported Period was $1.0 million, compared to revenue of $0.1 million in the Comparable
Period. This increase in revenue is related mainly to the consolidation of Vaso Healthcare IT Inc. (now Nanox Health IT Inc.) by the
Company.
Preliminary
Balance Sheet Data
On
a preliminary unaudited basis, the Company expects its cash, cash equivalents, short-term deposits and long-term restricted deposits
to be approximately $26.0 million as of September 30, 2026, as compared to $60.0 million as of December 31, 2025.
The
Company expects to continue to incur significant costs related to its ongoing operations. Management expects that the Company’s
cash and cash equivalents, and deposits, as of September 30, 2026, are not sufficient to support the Company’s operations under
its current operating plans for at least one year from the date of this press release. These factors raise substantial doubt as to the
Company’s ability to continue as a going concern. If the Company is unable to raise additional funds when needed, it may be required
to delay, reduce or eliminate its product development or future commercialization efforts, or grant rights to develop and market products
that it would otherwise prefer to develop and market itself.
About
Nanox
Nanox
(NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by delivering an integrated, end-to-end medical
imaging and healthcare services platform.
Nanox
combines affordable imaging hardware, advanced AI-based solutions, cloud-based software, access to remote radiology, health IT solutions,
and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care.
Nanox’s
vision is to expand the reach of medical imaging both within and beyond traditional hospital settings by providing a seamless solution
from scan to interpretation and beyond. By leveraging proprietary digital X-ray technology, AI-driven analytics, and a clinically driven
approach, Nanox aims to enhance the efficiency of routine imaging workflows, support early detection of disease, and improve patient
outcomes.
The
Nanox ecosystem includes Nanox.ARC, a cost-effective, 3D multi-source digital tomosynthesis imaging system designed for ease of use and
scalability; Nanox.AI, a suite of AI-based algorithms that augment the interpretation of routine CT imaging to identify early signs often
associated with chronic disease; Nanox.CLOUD, a cloud-based platform for secure data management, storage, and advanced imaging analytics;
Nanox.MARKETPLACE and USARAD Holdings, which provides access to remote radiology and cardiology experts and comprehensive teleradiology
services; and Nanox Health IT combines deep healthcare IT expertise with leading technology partners to deliver RIS, PACS, AI, dictation,
and secure infrastructure solutions that streamline workflows and support safer, more efficient care delivery.
By
integrating imaging technology, AI, cloud infrastructure, clinical expertise, a marketplace, and health information technology, Nanox
seeks to lower barriers to adoption, improve utilization, and advance preventive care worldwide. For more information, please visit https://www.nanox.vision.
Forward-Looking
Statements
This
press release contains forward-looking statements that are subject to risks and uncertainties. All statements that are not historical
facts contained in this press release are forward-looking statements preliminary unaudited revenue, revenue by category, cash, cash equivalents, deposits and restricted
deposits; expected future operating costs, liquidity, going concern matters. Factors that could cause actual results to differ materially from those currently anticipated include:
risks related to (i) the preliminary and unaudited nature of the financial data included in this press release, the completion of the
Company’s financial closing procedures, final adjustments, management review and other internal review procedures and the Company’s
ongoing evaluation of potential impairment charges; (ii) Nanox’s ability to complete development of the Nanox System; (ii) Nanox’s
history of recurring losses and negative cash flows from operating activities, significant future commitments, the uncertainty regarding
the adequacy of Nanox’s liquidity to pursue its complete business objectives, substantial doubt regarding its ability to continue
as a going concern and its ability to raise additional capital on acceptable terms or at all; (iii) Nanox’s ability to complete
development of the Nanox System and successfully demonstrate the feasibility of its technology for commercial applications; (iv) Nanox’s
expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding
its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance with applicable quality standards
and regulatory requirements; (v) Nanox’s ability to complete installations, commercially activate sites, support physician outreach
and generate anticipated revenue from its imaging systems, AI and software solutions and teleradiology services; (vi) Nanox’s ability
to realize the anticipated benefits of acquisitions, distribution arrangements and other commercial agreements, including annual minimum
purchase commitments, which may be affected by, among other things, competition, customer adoption, brand recognition, integration risks,
the ability of acquired businesses to grow and manage growth profitably and retain key employees; (vii) Nanox’s ability to enter
into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; (viii)
market acceptance of the Nanox System and the proposed pay-per-scan business model; (ix) Nanox’s expectations regarding collaborations
with third parties and their potential benefits; (x) Nanox’s ability to conduct business globally; (xi) changes in global, political,
economic, business, competitive, market and regulatory forces; (xii) risks related to the current conflict between the United States
(and, at times, Israel), on the one hand, and Iran and its proxies, on the other hand, and any adverse impact of that conflict on Israel;
and (xiii) risks related to litigation, which may result in significant liability and damage to the Company’s reputation.
For
a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox’s actual results to
differ from those contained in forward-looking statements or from the preliminary unaudited financial data furnished in this press release,
please see the section titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year ended December 31,
2025, filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 30, 2026, and in subsequent documents
filed with, or furnished to, the SEC by Nanox. The reader should not place undue reliance on any forward-looking statements or preliminary
unaudited financial data included in this press release. Except as required by law, Nanox undertakes no obligation to update publicly
any forward-looking statements or preliminary unaudited financial data after the date of this press release to conform these statements
or data to actual results or to changes in Nanox’s expectations.
